Table 1.
Patient characteristics.
| Patient Characteristics | Responders n = 19 |
Non-Responders n = 38 |
|---|---|---|
| Age *; years; median (range) | 61 (49–83) | 66 (47–84) |
| Sex; n (%) | ||
| Female | 7 (37) | 20 (53) |
| Male | 12 (63) | 18 (47) |
| Immunoglobulin subtype *; n (%) | ||
| IgG | 12 (63) | 25 (66) |
| IgA | 1 (5) | 3 (8) |
| Light-chain only | 6 (32) | 9 (23.5) |
| Non secretory | 0 (0) | 1 (2.5) |
| ISS *; n(%) | ||
| I | 5 (26) | 13 (34) |
| II | 8 (42) | 8 (21) |
| III | 4 (21) | 5 (13) |
| Unknown | 2 (11) | 12 (32) |
| ECOG performance status *; n (%) | ||
| 0 | 9 (47) | 20 (53) |
| 1 | 7 (37) | 6 (16) |
| 2 | 0 (0) | 0 (0) |
| 3 | 0 (0) | 2 (5) |
| Unknown | 3 (16) | 10 (26) |
| Fluorescence in situ hybridization §; n (%) | ||
| High-risk | 1 (5) | 9 (24) |
| Standard-risk | 15 (79) | 19 (50) |
| Unknown | 3 (16) | 10 (26) |
| Number of prior lines of therapy; median (range) | 2 (1–5) | 4 (0–17) |
* = at the time of diagnosis of multiple myeloma. § = If assessed more than once, the most recent result prior to initiation of DARA treatment is shown. High-risk aberrations were defined by the presence of either t(4;14), t(14;16) or del17p, each detected with a cut-off of 10% according to national standards for cytogenetic evaluation [45].